{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:22:28Z","timestamp":1790421748631,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Our objective was to evaluate whether having a germline variant of uncertain significance (VUS) influenced the decision to undergo bilateral mastectomy (BLMast) among lumpectomy-eligible patients with unilateral breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included 326 lumpectomy-eligible patients with non-metastatic breast cancer who underwent genetic testing at a single academic center between April 2020 and November 2021. Patients with pathogenic\/likely pathogenic variants or contraindications to breast-conserving therapy based on treating surgeon documentation were excluded. The primary outcome was BLMast. Multivariate logistic regression was used to assess the association between VUS results and surgical choice, while adjusting for age, stage, body mass index, family history, and other clinical factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 326 patients who underwent genetic testing and did not carry a pathogenic\/likely pathogenic variant, 235 (72.1%) had negative results and 91 (27.9%) had a VUS. A higher proportion of patients with a VUS underwent BLMast than those with negative results (39.7% vs. 24.8%, p\u2009=\u20090.026). On multivariate analysis, patients with VUS were more than twice as likely to undergo BLMast (odds ratio [OR] 2.213; 95% confidence interval [CI] 1.113\u20134.400; p\u2009=\u20090.023). Other independent predictors included age &lt;\u00a050\u00a0years (OR 3.203; 95% CI 1.615\u20136.354;\n                      <jats:italic>p\u2009<\/jats:italic>\n                      &lt;\u20090.001) and American Joint Committee on Cancer stage III disease (OR 7.065; 95% CI 1.067\u201346.788; p\u2009=\u20090.043).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among lumpectomy-eligible patients with unilateral breast cancer, a VUS result on germline genetic testing was independently associated with an increased likelihood of BLMast. These findings should be viewed as hypothesis-generating and underscore the need for improved education and standardized counseling surrounding VUS results to support informed surgical decision-making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-20427-4","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T13:01:16Z","timestamp":1789650076000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Influence of Variant of Uncertain Significance (VUS) Genetic Testing Results on Mastectomy Choice in Lumpectomy-Eligible Patients"],"prefix":"10.1245","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7716-5995","authenticated-orcid":false,"given":"Osvaldo","family":"Nunez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasanth","family":"Govind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tizita","family":"Wolde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainya","family":"Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas Panqueva","family":"Baena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talia R.","family":"Donenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Silva-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie B.","family":"Jeanjean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha A.","family":"Greenseid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Crystal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan B.","family":"Kesmodel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin E.","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"20427_CR1","doi-asserted-by":"crossref","unstructured":"NIH consensus conference. Treatment of early-stage breast cancer. JAMA. 1991;265(3):391-395.","DOI":"10.1001\/jama.1991.03460030097037"},{"issue":"7","key":"20427_CR2","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1001\/jamasurg.2017.0115","volume":"152","author":"R Nash","year":"2017","unstructured":"Nash R, Goodman M, Lin CC, et al. State variation in the receipt of a contralateral prophylactic mastectomy among women who received a diagnosis of invasive unilateral early-stage breast cancer in the United States, 2004\u20132012. JAMA Surg. 2017;152(7):648\u201357. https:\/\/doi.org\/10.1001\/jamasurg.2017.0115.","journal-title":"JAMA Surg."},{"issue":"8","key":"20427_CR3","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1001\/jamasurg.2020.0322","volume":"155","author":"T Wang","year":"2020","unstructured":"Wang T, Baskin AS, Dossett LA. Deimplementation of the choosing Wisely recommendations for low-value breast cancer surgery: a systematic review. JAMA Surg. 2020;155(8):759\u201370. https:\/\/doi.org\/10.1001\/jamasurg.2020.0322.","journal-title":"JAMA Surg."},{"issue":"6","key":"20427_CR4","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1001\/jamasurg.2020.6664","volume":"156","author":"DW Lim","year":"2021","unstructured":"Lim DW, Metcalfe KA, Narod SA. Bilateral mastectomy in women with unilateral breast cancer: a review. JAMA Surg. 2021;156(6):569\u201376. https:\/\/doi.org\/10.1001\/jamasurg.2020.6664.","journal-title":"JAMA Surg."},{"issue":"9","key":"20427_CR5","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1001\/jama.2014.10707","volume":"312","author":"AW Kurian","year":"2014","unstructured":"Kurian AW, Lichtensztajn DY, Keegan TH, Nelson DO, Clarke CA, Gomez SL. Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998\u20132011. JAMA. 2014;312(9):902\u201314. https:\/\/doi.org\/10.1001\/jama.2014.10707.","journal-title":"JAMA."},{"issue":"suppl 3","key":"20427_CR6","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1245\/s10434-010-1259-x","volume":"17","author":"CC Stucky","year":"2010","unstructured":"Stucky CC, Gray RJ, Wasif N, Dueck AC, Pockaj BA. Increase in contralateral prophylactic mastectomy: echoes of a bygone era? surgical trends for unilateral breast cancer. Ann Surg Oncol. 2010;17(suppl 3):330\u20137. https:\/\/doi.org\/10.1245\/s10434-010-1259-x.","journal-title":"Ann Surg Oncol."},{"issue":"33","key":"20427_CR7","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1200\/JCO.2007.12.3141","volume":"25","author":"TM Tuttle","year":"2007","unstructured":"Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol. 2007;25(33):5203\u20139. https:\/\/doi.org\/10.1200\/JCO.2007.12.3141.","journal-title":"J Clin Oncol."},{"issue":"10","key":"20427_CR8","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1245\/s10434-009-0641-z","volume":"16","author":"AK Arrington","year":"2009","unstructured":"Arrington AK, Jarosek SL, Virnig BA, Habermann EB, Tuttle TM. Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer. Ann Surg Oncol. 2009;16(10):2697\u2013704. https:\/\/doi.org\/10.1245\/s10434-009-0641-z.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"20427_CR9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jamcollsurg.2015.03.033","volume":"221","author":"L Grimmer","year":"2015","unstructured":"Grimmer L, Liederbach E, Velasco J, Pesce C, Wang CH, Yao K. Variation in contralateral prophylactic mastectomy rates according to racial groups in young women with breast cancer, 1998 to 2011: a report from the National Cancer Data Base. J Am Coll Surg. 2015;221(1):187\u201396. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2015.03.033.","journal-title":"J Am Coll Surg."},{"issue":"3","key":"20427_CR10","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1001\/jamasurg.2016.4749","volume":"152","author":"R Jagsi","year":"2017","unstructured":"Jagsi R, Hawley ST, Griffith KA, et al. Contralateral prophylactic mastectomy decisions in a population-based sample of patients with early-stage breast cancer. JAMA Surg. 2017;152(3):274\u201382. https:\/\/doi.org\/10.1001\/jamasurg.2016.4749.","journal-title":"JAMA Surg."},{"key":"20427_CR11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.breast.2018.05.001","volume":"40","author":"Q You","year":"2018","unstructured":"You Q, Chen K, Li Y, et al. Factors associated with the increasing trend of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ: analysis of Surveillance, Epidemiology, and End Results data. Breast. 2018;40:147\u201355. https:\/\/doi.org\/10.1016\/j.breast.2018.05.001.","journal-title":"Breast."},{"issue":"2","key":"20427_CR12","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3390\/cancers12020378","volume":"12","author":"Z Hyder","year":"2020","unstructured":"Hyder Z, Harkness EF, Woodward ER, et al. Risk of contralateral breast cancer in women with and without pathogenic variants in BRCA1, BRCA2, and TP53 genes in women with very early-onset (<36 years) breast cancer. Cancers (Basel). 2020;12(2):378. https:\/\/doi.org\/10.3390\/cancers12020378.","journal-title":"Cancers (Basel)."},{"key":"20427_CR13","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.breast.2014.10.005","volume":"23","author":"E Molina-Montes","year":"2014","unstructured":"Molina-Montes E, P\u00e9rez-Nevot B, Poll\u00e1n M, S\u00e1nchez-Cantalejo E, Esp\u00edn J, S\u00e1nchez MJ. Cumulative risk of second primary contralateral breast cancer in BRCA1\/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysis. Breast. 2014;23:721\u201342. https:\/\/doi.org\/10.1016\/j.breast.2014.10.005.","journal-title":"Breast."},{"key":"20427_CR14","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1002\/cam4.5202","volume":"12","author":"S Makhnoon","year":"2023","unstructured":"Makhnoon S, Levin B, Ensinger M, et al. A multicenter study of clinical impact of variant of uncertain significance reclassification in breast, ovarian and colorectal cancer susceptibility genes. Cancer Med. 2023;12:2875\u201384. https:\/\/doi.org\/10.1002\/cam4.5202.","journal-title":"Cancer Med."},{"issue":"6","key":"20427_CR15","doi-asserted-by":"publisher","first-page":"248","DOI":"10.6004\/jnccn.2025.7011","volume":"23","author":"SM Nielsen","year":"2025","unstructured":"Nielsen SM, Russell EM, Ellsworth RE, et al. Utilization of cancer screening, prevention, and treatment in women with variants of uncertain significance in breast cancer susceptibility genes. J Natl Compr Canc Netw. 2025;23(6):248\u201354. https:\/\/doi.org\/10.6004\/jnccn.2025.7011.","journal-title":"J Natl Compr Canc Netw."},{"issue":"6","key":"20427_CR16","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/jgc4.1422","volume":"30","author":"C Menke","year":"2021","unstructured":"Menke C, Nagaraj CB, Dawson B, He H, Tawde S, Wakefield EG. Understanding and interpretation of a variant of uncertain significance (VUS) genetic test result by pediatric providers who do not specialize in genetics. J Genet Couns. 2021;30(6):1559\u201369. https:\/\/doi.org\/10.1002\/jgc4.1422.","journal-title":"J Genet Couns."},{"issue":"16_suppl","key":"20427_CR17","doi-asserted-by":"publisher","first-page":"10512","DOI":"10.1200\/jco.2024.42.16_suppl.10512","volume":"42","author":"AW Kurian","year":"2024","unstructured":"Kurian AW, Hughes KS, Nielsen Young SM, et al. Real-world cancer care utilization among patients with breast cancer with germline variants of uncertain significance. J Clin Oncol. 2024;42(16_suppl):10512\u201310512. https:\/\/doi.org\/10.1200\/jco.2024.42.16_suppl.10512.","journal-title":"J Clin Oncol."},{"issue":"2","key":"20427_CR18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, et al. Research Electronic Data Capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform."},{"key":"20427_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software partners. J Biomed Inform. 2019;95:103208.","journal-title":"J Biomed Inform."},{"issue":"8","key":"20427_CR20","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamaoncol.2018.0644","volume":"4","author":"AW Kurian","year":"2018","unstructured":"Kurian AW, Ward KC, Hamilton AS, et al. Uptake, results, and outcomes of germline multiple-gene sequencing after diagnosis of breast cancer. JAMA Oncol. 2018;4(8):1066\u201372. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0644.","journal-title":"JAMA Oncol."},{"issue":"4","key":"20427_CR21","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.6400","volume":"6","author":"AW Kurian","year":"2020","unstructured":"Kurian AW, Ward KC, Abrahamse P, et al. Association of germline genetic testing results with locoregional and systemic therapy in patients with breast cancer. JAMA Oncol. 2020;6(4):e196400. https:\/\/doi.org\/10.1001\/jamaoncol.2019.6400.","journal-title":"JAMA Oncol."},{"issue":"9","key":"20427_CR22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.32787","volume":"5","author":"PW Whitworth","year":"2022","unstructured":"Whitworth PW, Beitsch PD, Patel R, et al. Clinical utility of universal germline genetic testing for patients with breast cancer. JAMA Netw Open. 2022;5(9):e2232787. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.32787.","journal-title":"JAMA Netw Open."},{"issue":"6","key":"20427_CR23","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1002\/pon.4683","volume":"27","author":"SM Rosenberg","year":"2018","unstructured":"Rosenberg SM, Greaney ML, Patenaude AF, Sepucha KR, Meyer ME, Partridge AH. I don\u2019t want to take chances: a qualitative exploration of surgical decision making in young breast cancer survivors. Psychooncology. 2018;27(6):1524\u20139. https:\/\/doi.org\/10.1002\/pon.4683.","journal-title":"Psychooncology."},{"key":"20427_CR24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.breast.2018.03.011","volume":"39","author":"I Spronk","year":"2018","unstructured":"Spronk I, Schellevis FG, Burgers JS, de Bock GH, Korevaar JC. Incidence of isolated local breast cancer recurrence and contralateral breast cancer: A systematic review. Breast. 2018;39:70\u20139. https:\/\/doi.org\/10.1016\/j.breast.2018.03.011.","journal-title":"Breast."},{"key":"20427_CR25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2147\/IJWH.S52380","volume":"7","author":"KR Davies","year":"2015","unstructured":"Davies KR, Cantor SB, Brewster AM. Better contralateral breast cancer risk estimation and alternative options to contralateral prophylactic mastectomy. Int J Womens Health. 2015;7:181\u20137. https:\/\/doi.org\/10.2147\/IJWH.S52380.","journal-title":"Int J Womens Health."},{"key":"20427_CR26","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12957-015-0638-y","volume":"13","author":"NN Basu","year":"2015","unstructured":"Basu NN, Ross GL, Evans DG, Barr L. The Manchester guidelines for contralateral risk-reducing mastectomy. World J Surg Oncol. 2015;13:237. https:\/\/doi.org\/10.1186\/s12957-015-0638-y.","journal-title":"World J Surg Oncol."},{"issue":"4","key":"20427_CR27","doi-asserted-by":"publisher","first-page":"CD002748","DOI":"10.1002\/14651858.CD002748.pub4","volume":"4","author":"NE Carbine","year":"2018","unstructured":"Carbine NE, Lostumbo L, Wallace J, Ko H. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst Rev. 2018;4(4):CD002748. https:\/\/doi.org\/10.1002\/14651858.CD002748.pub4.","journal-title":"Cochrane Database Syst Rev."},{"issue":"3","key":"20427_CR28","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/SLA.0000000000001698","volume":"265","author":"SM Wong","year":"2017","unstructured":"Wong SM, Freedman RA, Sagara Y, Aydogan F, Barry WT, Golshan M. Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer. Ann Surg. 2017;265(3):581\u20139. https:\/\/doi.org\/10.1097\/SLA.0000000000001698.","journal-title":"Ann Surg."},{"issue":"2","key":"20427_CR29","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1245\/s10434-016-5688-z","volume":"24","author":"KK Hunt","year":"2017","unstructured":"Hunt KK, Euhus DM, Boughey JC, et al. Society of Surgical Oncology Breast Disease Working Group Statement on Prophylactic (Risk-Reducing) Mastectomy. Ann Surg Oncol. 2017;24(2):375\u201397. https:\/\/doi.org\/10.1245\/s10434-016-5688-z.","journal-title":"Ann Surg Oncol."},{"issue":"10","key":"20427_CR30","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1245\/s10434-016-5443-5","volume":"23","author":"JC Boughey","year":"2016","unstructured":"Boughey JC, Attai DJ, Chen SL, et al. Contralateral prophylactic mastectomy (CPM) consensus statement from the American Society of Breast Surgeons: data on CPM outcomes and risks. Ann Surg Oncol. 2016;23(10):3100\u20135. https:\/\/doi.org\/10.1245\/s10434-016-5443-5.","journal-title":"Ann Surg Oncol."},{"issue":"9","key":"20427_CR31","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1245\/s10434-014-3687-5","volume":"21","author":"SM Sharpe","year":"2014","unstructured":"Sharpe SM, Liederbach E, Czechura T, Pesce C, Winchester DJ, Yao K. Impact of bilateral versus unilateral mastectomy on short term outcomes and adjuvant therapy, 2003\u20132010: a report from the National Cancer Data Base. Ann Surg Oncol. 2014;21(9):2920\u20137. https:\/\/doi.org\/10.1245\/s10434-014-3687-5.","journal-title":"Ann Surg Oncol."},{"issue":"15 suppl","key":"20427_CR32","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.2020.38.15_suppl.570","volume":"38","author":"DW Lim","year":"2020","unstructured":"Lim DW, Retrouvey H, Kerrebijn I, et al. Psychosocial outcomes following surgery in women with unilateral, nonhereditary breast cancer [abstract]. J Clin Oncol. 2020;38(15 suppl):570. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.570.","journal-title":"J Clin Oncol."},{"issue":"15","key":"20427_CR33","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/j.ejca.2005.02.037","volume":"41","author":"YM Kirova","year":"2005","unstructured":"Kirova YM, Stoppa-Lyonnet D, Savignoni A, et al. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer. 2005;41(15):2304\u201311. https:\/\/doi.org\/10.1016\/j.ejca.2005.02.037.","journal-title":"Eur J Cancer."},{"issue":"23","key":"20427_CR34","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402\u201316. https:\/\/doi.org\/10.1001\/jama.2017.7112.","journal-title":"JAMA."},{"issue":"4","key":"20427_CR35","doi-asserted-by":"publisher","first-page":"e472","DOI":"10.1200\/OP.21.00322","volume":"18","author":"V Ro","year":"2022","unstructured":"Ro V, McGuinness JE, Guo B, et al. Association between genetic testing for hereditary breast cancer and contralateral prophylactic mastectomy among multiethnic women diagnosed with early-stage breast cancer. JCO Oncol Pract. 2022;18(4):e472\u201383. https:\/\/doi.org\/10.1200\/OP.21.00322.","journal-title":"JCO Oncol Pract."},{"issue":"15","key":"20427_CR36","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1200\/JCO.2017.77.3424","volume":"36","author":"AS Reiner","year":"2018","unstructured":"Reiner AS, Sisti J, John EM, et al. Breast cancer family history and contralateral breast cancer risk in young women: an update from the Women\u2019s Environmental Cancer and Radiation Epidemiology Study. J Clin Oncol. 2018;36(15):1513\u201320. https:\/\/doi.org\/10.1200\/JCO.2017.77.3424.","journal-title":"J Clin Oncol."},{"key":"20427_CR37","unstructured":"National Cancer Institute. Hormone therapy for breast cancer. 2012. http:\/\/www.cancer.gov\/cancertopics\/types\/breast\/breast-hormone-therapy-fact-sheet"},{"issue":"2","key":"20427_CR38","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10552-024-01900-5","volume":"36","author":"R Ghosh","year":"2025","unstructured":"Ghosh R, Pfeiffer RM, Roberts S, Gierach GL, Dallal CM. Adjuvant endocrine therapy and risk of contralateral breast cancer: a systematic review and meta-analysis of observational studies. Cancer Causes Control. 2025;36(2):107\u201326. https:\/\/doi.org\/10.1007\/s10552-024-01900-5.","journal-title":"Cancer Causes Control."},{"issue":"80","key":"20427_CR39","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jss.2022.06.066","volume":"2","author":"PA Borowsky","year":"2022","unstructured":"Borowsky PA, Choi S, Moore JF, et al. The association of preoperative magnetic resonance imaging (MRI) with surgical management in patients with early-stage breast cancer. J Surg Res. 2022;2(80):114\u201322. https:\/\/doi.org\/10.1016\/j.jss.2022.06.066.","journal-title":"J Surg Res."},{"key":"20427_CR40","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/jso.25315","volume":"119","author":"H Panchal","year":"2019","unstructured":"Panchal H, Pilewskie ML, Sheckter CC, et al. National trends in contralateral prophylactic mastectomy in women with locally advanced breast cancer. J Surg Oncol. 2019;119:79\u201387. https:\/\/doi.org\/10.1002\/jso.25315.","journal-title":"J Surg Oncol."},{"key":"20427_CR41","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1245\/s10434-016-5367-0","volume":"23","author":"BL Murphy","year":"2016","unstructured":"Murphy BL, Hoskin TL, Boughey JC, et al. Contralateral prophylactic mastectomy for women with T4 locally advanced breast cancer. Ann Surg Oncol. 2016;23:3365\u201370. https:\/\/doi.org\/10.1245\/s10434-016-5367-0.","journal-title":"Ann Surg Oncol."},{"key":"20427_CR42","doi-asserted-by":"publisher","first-page":"8628","DOI":"10.1245\/s10434-025-17448-w","volume":"32","author":"S Tapiavala","year":"2025","unstructured":"Tapiavala S, Liu Y, Roy S, et al. Impact of national society guidelines and national comprehensive cancer network (NCCN) guidelines on genetic testing use among patients with breast cancer. Ann Surg Oncol. 2025;32:8628\u201335. https:\/\/doi.org\/10.1245\/s10434-025-17448-w.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"20427_CR43","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/cge.12488","volume":"88","author":"A Yorczyk","year":"2015","unstructured":"Yorczyk A, Robinson LS, Ross TS. Use of panel tests in place of single gene tests in the cancer genetics clinic. Clin Genet. 2015;88(3):278\u201382. https:\/\/doi.org\/10.1111\/cge.12488.","journal-title":"Clin Genet."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20427-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20427-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20427-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T13:01:19Z","timestamp":1789650079000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20427-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":43,"alternative-id":["20427"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20427-4","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"27 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kristin Rojas has received speaker honoraria from Pacira pharmaceuticals, has consulted for Novartis and Merck, and has received National Institutes of Health funding (effort during time period of manuscript preparation but not directly related to submitted work; P30 Supplement \"Early-Stage Surgeon Scientist Program (ESSP)\" [grant 025134_Supp5]).","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors declare that they have no confl icts of interests or competing interests relevant to the content of thisarticle.","order":2,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Ethics"}}]}}